Mechanisms and Clinical Evidence of the Pleiotropic Effects of the Hydroxy-Methyl-Glutaryl-CoA Reductase Inhibitors in Central Nervous System Disorders: A Comprehensive Review

REFERENCES

• Smith SC Jr, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, Grundy SM, Hiratzka L, Jones D, Krumholz HM, Mosca L, Pasternak RC, Pearson T, Pfeffer MA, Taubert KA. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update. Circulation. 2006;113:2363–72.
   PubMed Web of Science ®Google Scholar
• Pearson TA, Blair SN, Daniels SR, Eckel RH, Fair JM, Fortmann SP, Franklin BA, Goldstein LB, Greenland P, Grundy SM, Hong Y, Miller NH, Lauer RM, Ockene IS, Sacco RL, Sallis JF Jr, Smith SC Jr, Stone NJ, Taubert KA. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation. 2002;106(3):388–91.
   PubMed Web of Science ®Google Scholar
• Mihos CG, Artola RT, Santana O. The pleiotropic effects of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in rheumatologic disorders: a comprehensive review. Rheumatol Int. 2012;32(2):287–94.
   PubMed Web of Science ®Google Scholar
• Mihos CG, Santana O. Pleiotropic effects of the HMG-CoA reductase inhibitors. Int J Gen Med. 2011;4:261–71.
   PubMedGoogle Scholar
• Mihos CG, Salas MJ, Santana O. The pleiotropic effects of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in cardiovascular disease: a comprehensive review. Cardiol Rev. 2010;18(6):298–304.
   PubMed Web of Science ®Google Scholar
• Tandon V, Bano G, Khajuria V, Parihar A, Gupta S. Pleiotropic effects of statins. Indian J Pharmacol. 2005;37(2):77–85.
   Google Scholar
• Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol. 2005;45:89–118.
   PubMed Web of Science ®Google Scholar
• Everett BM, Glynn RJ, MacFadyen JG, Ridker PM. Rosuvastatin in the prevention of stroke among men and women with elevated levels of C-reactive protein: justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER). Circulation. 2010;121(1):143–50.
   PubMed Web of Science ®Google Scholar
• Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M, Rudolph AE, Sillesen H, Simunovic L, Szarek M, Welch KM, Zivin JA. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355(6):549–59.
   PubMed Web of Science ®Google Scholar
• Ni Chróinín D, Callaly EL, Duggan J, Merwick Á, Hannon N, Sheehan Ó, Marnane M, Horgan G, Williams EB, Harris D, Kyne L, McCormack PM, Moroney J, Grant T, Williams D, Daly L, Kelly PJ. Association between acute statin therapy, survival, and improved functional outcome after ischemic stroke: the North Dublin Population Stroke Study. Stroke. 2011;42(4):1021–29.
   PubMed Web of Science ®Google Scholar
• Putaala J, Haapaniemi E, Kaste M, Tatlisumak T. Statins after ischemic stroke of undetermined etiology in young adults. Neurology. 2011;77(5):426–30.
   PubMed Web of Science ®Google Scholar
• Amarenco P, Labreuche J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol. 2009;8(5):453–63.
   PubMed Web of Science ®Google Scholar
• Sugawara T, Ayer R, Zhang JH. Role of statins in cerebral vasospasm. Acta Neurochir Suppl. 2008;104:287–90.
   PubMedGoogle Scholar
• Lapchak PA, Han MK. The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor simvastatin reduces thrombolytic-induced intracerebral hemorrhage in embolized rabbits. Brain Res. 2009;1303:144–50.
   PubMed Web of Science ®Google Scholar
• Sterzer P, Meintzschel F, Rösler A, Lanfermann H, Steinmetz H, Sitzer M. Pravastatin improves cerebral vasomotor reactivity in patients with subcortical small-vessel disease. Stroke. 2001;32(12):2817–20.
   PubMed Web of Science ®Google Scholar
• Chen J, Zhang ZG, Li Y, Wang Y, Wang L, Jiang H, Zhang C, Lu M, Katakowski M, Feldkamp CS, Chopp M. Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke. Ann Neurol. 2003;53(6):743–51.
   PubMed Web of Science ®Google Scholar
• Endres M, Laufs U, Huang Z, Nakamura T, Huang P, Moskowitz MA, Liao JK. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci USA. 1998;95(15):8880–85.
   PubMed Web of Science ®Google Scholar
• Sironi L, Cimino M, Guerrini U, Calvio AM, Lodetti B, Asdente M, Balduini W, Paoletti R, Tremoli E. Treatment with statins after induction of focal ischemia in rats reduces the extent of brain damage. Arterioscler Thromb Vasc Biol. 2003;23(2):322–27.
   PubMed Web of Science ®Google Scholar
• Collins R, Armitage J, Parish S, Sleight P, Peto R. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet. 2004;363(9411):757–67.
   PubMed Web of Science ®Google Scholar
• Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M, Rudolph AE, Sillesen H, Simunovic L, Szarek M, Welch KM, Zivin JA. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355(6):549–56.
   PubMed Web of Science ®Google Scholar
• Squizzato A, Romualdi E, Dentali F, Ageno W. Statins for acute ischemic stroke. Cochrane Database Syst Rev. 2011;(8):CD007551.
   Google Scholar
• Flint AC, Kamel H, Navi BB, Rao VA, Faigeles BS, Conell C, Klingman JG, Sidney S, Hills NK, Sorel M, Cullen SP, Johnston SC. Statin use during ischemic stroke hospitalization is strongly associated with improved poststroke survival. Stroke. 2012;43(1):147–54.
   PubMed Web of Science ®Google Scholar
• Blanco M, Nombela F, Castellanos M, Rodriguez-Yáñez M, García-Gil M, Leira R, Lizasoain I, Serena J, Vivancos J, Moro MA, Dávalos A, Castillo J. Statin treatment withdrawal in ischemic stroke: a controlled randomized study. Neurology. 2007;69(9):904–10.
   PubMed Web of Science ®Google Scholar
• Vergouwen MD, de Haan RJ, Vermeulen M, Roos YB. Statin treatment and the occurrence of hemorrhagic stroke in patients with a history of cerebrovascular disease. Stroke. 2008;39(2):497–502.
   PubMed Web of Science ®Google Scholar
• Goldstein LB, Amarenco P, Szarek M, Callahan A 3rd, Hennerici M, Sillesen H, Zivin JA, Welch KM. Hemorrhagic stroke in the stroke prevention by aggressive reduction in cholesterol levels study. Neurology. 2008;70(24 Pt 2):2364–70.
   PubMed Web of Science ®Google Scholar
• Hackam DG, Woodward M, Newby LK, Bhatt DL, Shao M, Smith EE, Donner A, Mamdani M, Douketis JD, Arima H, Chalmers J, MacMahon S, Tirschwell DL, Psaty BM, Bushnell CD, Aguilar MI, Capampangan DJ, Werring DJ, De Rango P, Viswanathan A, Danchin N, Cheng CL, Yang YH, Verdel BM, Lai MS, Kennedy J, Uchiyama S, Yamaguchi T, Ikeda Y, Mrkobrada M. Statins and intracerebral hemorrhage: collaborative systematic review and meta-analysis. Circulation. 2011;124(20):2233–42.
   PubMed Web of Science ®Google Scholar
• Biffi A, Devan WJ, Anderson CD, Ayres AM, Schwab K, Cortellini L, Viswanathan A, Rost NS, Smith EE, Goldstein JN, Greenberg SM, Rosand J. Statin use and outcome after intracerebral hemorrhage: case-control study and meta-analysis. Neurology. 2011;76(18):1581–88.
   PubMed Web of Science ®Google Scholar
• Woo D, Sauerbeck LR, Kissela BM, Khoury JC, Szaflarski JP, Gebel J, Shukla R, Pancioli AM, Jauch EC, Menon AG, Deka R, Carrozzella JA, Moomaw CJ, Fontaine RN, Broderick JP. Genetic and environmental risk factors for intracerebral hemorrhage: preliminary results of a population-based study. Stroke. 2002;33(5):1190–95.
   PubMed Web of Science ®Google Scholar
• Rosand J, Hylek EM, O'Donnell HC, Greenberg SM. Warfarin-associated hemorrhage and cerebral amyloid angiopathy: a genetic and pathologic study. Neurology. 2000;55(7):947–51.
   PubMed Web of Science ®Google Scholar
• Westover MB, Bianchi MT, Eckman MH, Greenberg SM. Statin use following intracerebral hemorrhage: a decision analysis. Arch Neurol. 2011;68(5):573–79.
   PubMedGoogle Scholar
• Sillberg VA, Wells GA, Perry JJ. Do statins improve outcomes and reduce the incidence of vasospasm after aneurysmal subarachnoid hemorrhage: a meta-analysis. Stroke. 2008;39(9):2622–26.
   PubMed Web of Science ®Google Scholar
• Kramer AH, Fletcher JJ. Statins in the management of patients with aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis. Neurocrit Care. 2010;12(2): 285–96.
   PubMed Web of Science ®Google Scholar
• Markovic-Plese S, Singh AK, Singh I. Therapeutic potential of statins in multiple sclerosis: immune modulation, neuroprotection and neurorepair. Future Neurol. 2008;3(2):153.
   PubMedGoogle Scholar
• Weber MS, Zamvil SS. Statins and demyelination. Curr Top Microbiol Immunol. 2008;318:313–24.
   PubMed Web of Science ®Google Scholar
• Paintlia AS, Paintlia MK, Singh I, Skoff RB, Singh AK. Combination therapy of lovastatin and rolipram provides neuroprotection and promotes neurorepair in inflammatory demyelination model of multiple sclerosis. Glia. 2009;57(2):182–93.
   PubMed Web of Science ®Google Scholar
• Ifergan I, Wosik K, Cayrol R, Kébir H, Auger C, Bernard M, Bouthillier A, Moumdjian R, Duquette P, Prat A. Statins reduce human blood-brain barrier permeability and restrict leukocyte migration: relevance to multiple sclerosis. Ann Neurol. 2006;60(1):45–55.
   PubMed Web of Science ®Google Scholar
• Correale J, Villa A. The blood-brain-barrier in multiple sclerosis: functional roles and therapeutic targeting. Autoimmunity. 2007;40(2):148–60.
   PubMed Web of Science ®Google Scholar
• Miron VE, Rajasekharan S, Jarjour AA, Zamvil SS, Kennedy TE, Antel JP. Simvastatin regulates oligodendroglial process dynamics and survival. Glia. 2007;55(2):130–43.
   PubMed Web of Science ®Google Scholar
• Miron VE, Zehntner SP, Kuhlmann T, Ludwin SK, Owens T, Kennedy TE, Bedell BJ, Antel JP. Statin therapy inhibits remyelination in the central nervous system. Am J Pathol. 2009;174(5):1880–90.
   PubMed Web of Science ®Google Scholar
• Togha M, Karvigh SA, Nabavi M, Moghadam NB, Harirchian MH, Sahraian MA, Enzevaei A, Nourian A, Ghanaati H, Firouznia K, Jannati A, Shekiba M. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial. Mult Scler. 2010;16(7):848–54.
   PubMed Web of Science ®Google Scholar
• Lanzillo R, Orefice G, Quarantelli M, Rinaldi C, Prinster A, Ventrella G, Spitaleri D, Lus G, Vacca G, Carotenuto B, Salvatore E, Brunetti A, Tedeschi G, Brescia Morra V. Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy. Mult Scler. 2010;16(4):450–54.
   PubMed Web of Science ®Google Scholar
• Sorensen PS, Lycke J, Erälinna JP, Edland A, Wu X, Frederiksen JL, Oturai A, Malmeström C, Stenager E, Sellebjerg F, Sondergaard HB. Simvastatin as add-on therapy to interferon β-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomized phase 4 trial. Lancet Neurol. 2011;10(8):691–701.
   PubMed Web of Science ®Google Scholar
• Rudick RA, Pace A, Rani MR, Hyde R, Panzara M, Appachi S, Shrock J, Maurer SL, Calabresi PA, Confavreux C, Galetta SL, Lublin FD, Radue EW, Ransohoff RM. Effect of statins on clinical and molecular responses to intramuscular interferon beta-1a. Neurology. 2009;72(23):1989–93.
   PubMed Web of Science ®Google Scholar
• Birnbaum G, Cree B, Altafullah I, Zinser M, Reder AT. Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis. Neurology. 2008;71(18):1390–95.
   PubMed Web of Science ®Google Scholar
• Whitmer RA, Sidney S, Selby J, Johnston SC, Yaffe K. Midlife cardiovascular risk factors and risk of dementia in late life. Neurology. 2005;64(2):277–81.
   PubMed Web of Science ®Google Scholar
• Whitfield JF. Can statins put the breaks on Alzheimer's disease? Expert Opin Investig Drugs. 2006;15(12):1479–85.
   PubMed Web of Science ®Google Scholar
• Kurinami H, Sato N, Shinohara M, Takeuchi D, Takeda S, Shimamura M, Ogihara T, Morishita R. Prevention of amyloid beta-induced memory impairment by fluvastatin, associated with the decrease in amyloid beta accumulation and oxidative stress in amyloid beta injection mouse model. Int J Mol Med. 2008;21(5):531–37.
   PubMed Web of Science ®Google Scholar
• Wang Q, Yan J, Chen X, Li J, Yang Y, Weng J, Deng C, Yenari MA. Statins: multiple neuroprotective mechanisms in neurodegenerative diseases. Exp Neurol. 2011;230(1):27–34.
   PubMed Web of Science ®Google Scholar
• Harris JR, Milton NG. Cholesterol in Alzheimer's disease and other amyloidogenic disorders. Subcell Biochem. 2010;51:47–75.
   PubMedGoogle Scholar
• Boimel M, Grigoriadis N, Lourbopoulos A, Touloumi O, Rosenmann D, Abramsky O, Rosenmann H. Statins reduce the neurofibrillary tangle burden in a mouse model of tauopathy. J Neuropathol Exp Neurol. 2009;68(3):314–25.
   PubMed Web of Science ®Google Scholar
• Li G, Larson EB, Sonnen JA, Shofer JB, Petrie EC, Schantz A, Peskind ER, Raskind MA, Breitner JC, Montine TJ. Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease. Neurology. 2007;69(9):878–85.
   PubMed Web of Science ®Google Scholar
• Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA. 1997;277(10):813–17.
   PubMed Web of Science ®Google Scholar
• Carlsson CM, Gleason CE, Hess TM, Moreland KA, Blazel HM, Koscik RL, Schreiber NT, Johnson SC, Atwood CS, Puglielli L, Hermann BP, McBride PE, Stein JH, Sager MA, Asthana S. Effects of simvastatin on cerebrospinal fluid biomarkers and cognition in middle-aged adults at risk for Alzheimer's disease. J Alzheimers Dis. 2008;13(2): 187–97.
   PubMed Web of Science ®Google Scholar
• Sparks DL, Connor DJ, Sabbagh MN, Petersen RB, Lopez J, Browne P. Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer's disease: results of the Alzheimer's Disease Cholesterol-Lowering Treatment (ADCLT) trial. Acta Neurol Scand Suppl. 2006;185:3–7.
   PubMedGoogle Scholar
• Rockwood K, Fay S, Gorman M, Carver D, Graham JE. The clinical meaningfulness of ADAS-Cog changes in Alzheimer's disease patients treated with donepezil in an open-label trial. BMC Neurol. 2007;7:26.
   PubMed Web of Science ®Google Scholar
• Li G, Shofer JB, Rhew IC, Kukull WA, Peskind ER, McCormick W, Bowen JD, Schellenberg GD, Crane PK, Breitner JC, Larson EB. Age-varying association between statin use and incident Alzheimer's disease. J Am Geriatr Soc. 2010;58(7):1311–17.
   PubMed Web of Science ®Google Scholar
• Haag MD, Hofman A, Koudstaal PJ, Stricker BH, Breteler MM. Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. J Neurol Neurosurg Psychiatry. 2009;80(1):13–17.
   PubMed Web of Science ®Google Scholar
• Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet. 2000; 356(9242):1627–31.
   PubMed Web of Science ®Google Scholar
• Trompet S, van Vliet P, de Craen AJ, Jolles J, Buckley BM, Murphy MB, Ford I, Macfarlane PW, Sattar N, Packard CJ, Stott DJ, Shepherd J, Bollen EL, Blauw GJ, Jukema JW, Westendorp RG. Pravastatin and cognitive function in the elderly. Results of the PROSPER study. J Neurol. 2010;257(1):85–90.
   PubMed Web of Science ®Google Scholar
• Feldman HH, Doody RS, Kivipelto M, Sparks DL, Waters DD, Jones RW, Schwam E, Schindler R, Hey-Hadavi J, DeMicco DA, Breazna A. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology. 2010;74(12):956–64.
   PubMed Web of Science ®Google Scholar
• Rojas-Fernandez CH, Cameron JC. Is statin-associated cognitive impairment clinically relevant? A narrative review and clinical recommendations. Ann Pharmacother. 2012;46(4):549–57.
   PubMed Web of Science ®Google Scholar
• Ghosh A, Roy A, Matras J, Brahmachari S, Gendelman HE, Pahan K. Simvastatin inhibits the activation of p21ras and prevents the loss of dopaminergic neurons in a mouse model of Parkinson's disease. J Neurosci. 2009;29(43):13543–56.
   PubMed Web of Science ®Google Scholar
• Bar-On P, Crews L, Koob AO, Mizuno H, Adame A, Spencer B, Masliah E. Statins reduce neuronal alpha-synuclein aggregation in in vitro models of Parkinson's disease. J Neurochem. 2008;105(5):1656–67.
   PubMed Web of Science ®Google Scholar
• Koob AO, Ubhi K, Paulsson JF, Kelly J, Rockenstein E, Mante M, Adame A, Masliah E. Lovastatin ameliorates alpha-synuclein accumulation and oxidation in transgenic mouse models of alpha-synucleinopathies. Exp Neurol. 2010;221(2):267–74.
   PubMed Web of Science ®Google Scholar
• Yan J, Xu Y, Zhu C, Zhang L, Wu A, Yang Y, Xiong Z, Deng C, Huang XF, Yenari MA, Yang YG, Ying W, Wang Q. Simvastatin prevents dopaminergic neurodegeneration in experimental parkinsonian models: the association with anti-inflammatory responses. PLoS one. 2011;6(6):e20945.
   PubMed Web of Science ®Google Scholar
• Bessler H, Djaldetti R, Salman H, Bergman M, Djaldetti M. IL-1 beta, IL-2, IL-6 and TNF-alpha production by peripheral blood mononuclear cells from patients with Parkinson's disease. Biomed Pharmacother. 1999;53(3):141–45.
   PubMed Web of Science ®Google Scholar
• Roy A, Pahan K. Prospects of statins in Parkinson disease. Neuroscientist. 2011;17(3):244–55.
   PubMed Web of Science ®Google Scholar
• Wolozin B, Wang SW, Li NC, Lee A, Lee TA, Kazis LE. Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease. BMC Med. 2007;5:20.
   PubMed Web of Science ®Google Scholar
• Gao X, Simon KC, Schwarzschild MA, Ascherio A. Prospective study of statin use and risk of Parkinson disease. Arch Neurol. 2012;69(3):380–84.
   PubMed Web of Science ®Google Scholar
• Mutez E, Duhamel A, Defebvre L, Bordet R, Destée A, Kreisler A. Lipid-lowering drugs are associated with delayed onset and slower course of Parkinson's disease. Pharmacol Res. 2009;60(1):41–45.
   PubMed Web of Science ®Google Scholar
• Béziaud T, Ru Chen X, El Shafey N, Fréchou M, Teng F, Palmier B, Beray-Berthat V, Soustrat M, Margaill I, Plotkine M, Marchand-Leroux C, Besson VC. Simvastatin in traumatic brain injury: effect on brain edema mechanisms. Crit Care Med. 2011;39(10):2300–7.
   PubMed Web of Science ®Google Scholar
• Abrahamson EE, Ikonomovic MD, Dixon CE, DeKosky ST. Simvastatin therapy prevents brain trauma-induced increases in beta-amyloid peptide levels. Ann Neurol. 2009;66(3):407–14.
   PubMed Web of Science ®Google Scholar
• Wang H, Lynch JR, Song P, Yang HJ, Yates RB, Mace B, Warner DS, Guyton JR, Laskowitz DT. Simvastatin and atorvastatin improve behavioral outcome, reduce hippocampal degeneration, and improve cerebral blood flow after experimental traumatic brain injury. Exp Neurol. 2007;206(1):59–69.
   PubMed Web of Science ®Google Scholar
• Indraswari F, Wang H, Lei B, James ML, Kernagis D, Warner DS, Dawson HN, Laskowitz DT. Statins improve outcome in murine models of intracranial hemorrhage and traumatic brain injury: a translational approach. J Neurotrauma. 2012;29(7):1388–400.
   PubMed Web of Science ®Google Scholar
• Tapia-Perez JH, Sanchez-Aguilar M, Torres-Corzo JG, Gordillo-Moscoso A, Martinez-Perez P, Madeville P, de la Cruz-Mendoza E, Chalita-Williams J. Effect of rosuvastatin on amnesia and disorientation after traumatic brain injury (NCT003229758). J Neurotrauma. 2008;25(8):1011–17.
   PubMed Web of Science ®Google Scholar
• Schneider EB, Efron DT, MacKenzie EJ, Rivara FP, Nathens AB, Jurkovich GJ. Premorbid statin use is associated with improved survival and functional outcomes in older head-injured individuals. J Trauma. 2011;71(4):815–19.
   PubMedGoogle Scholar
• Edwards IR, Star K, Kiuru A. Statins, neuromuscular degenerative disease and an amyotrophic lateral sclerosis-like syndrome: an analysis of individual case safety reports from vigibase. Drug Saf. 2007;30(6):515–25.
   PubMed Web of Science ®Google Scholar
• Sørensen HT, Riis AH, Lash TL, Pedersen L. Statin use and risk of amyotrophic lateral sclerosis and other motor neuron disorders. Circ Cardiovasc Qual Outcomes. 2010;3(4):413–17.
   PubMed Web of Science ®Google Scholar
• Zinman L, Sadeghi R, Gawel M, Patton D, Kiss A. Are statin medications safe in patients with ALS? Amyotroph Lateral Scler. 2008;9(4):223–28.
   PubMed Web of Science ®Google Scholar
• Golomb BA, Kwon EK, Koperski S, Evans MA. Amyotrophic lateral sclerosis-like conditions in possible association with cholesterol-lowering drugs: an analysis of patient reports to the University of California, San Diego (UCSD) Statin Effects Study. Drug Saf. 2009;32(8):649–61.
   PubMed Web of Science ®Google Scholar
• Beltowski J. Statins and ALS: the possible role of impaired LXR signaling. Med Sci Monit. 2010;16(3):RA73–78.
   PubMed Web of Science ®Google Scholar
• Pugh MJ, Knoefel JE, Mortensen EM, Amuan ME, Berlowitz DR, Van Cott AC. New-onset epilepsy risk factors in older veterans. J Am Geriatr Soc. 2009;57(2):237–42.
   PubMed Web of Science ®Google Scholar
• Cemeus C, Zhao TT, Barrett GM, Lorimer IA, Dimitroulakos J. Lovastatin enhances gefitinib activity in glioblastoma cells irrespective of EGFRvIII and PTEN status. J Neurooncol. 2008;90(1):9–17.
   PubMed Web of Science ®Google Scholar
• Bar EE, Stearns D. New developments in medulloblastoma treatment: the potential of a cyclopamine-lovastatin combination. Expert Opin Investig Drugs. 2008;17(2):185–95.
   PubMed Web of Science ®Google Scholar
• Li XL, Dou YC, Liu Y, Shi CW, Cao LL, Zhang XQ, Zhu J, Duan RS. Atorvastatin ameliorates experimental autoimmune neuritis by decreased Th1/Th17 cytokines and up-regulated T regulatory cells. Cell Immunol. 2011;271(2):455–61.
   PubMed Web of Science ®Google Scholar
• Sarkey JP, Richards MP, Stubbs EB Jr. Lovastatin attenuates nerve injury in an animal model of Guillain-Barré syndrome. J Neurochem. 2007;100(5):1265–77.
   PubMed Web of Science ®Google Scholar
• Tsakiri A, Tsiantoulas D, Frederiksen J, Svane IM. Increased immunopotency of monocyte derived dendritic cells from patients with optic neuritis is inhibited in vitro by simvastatin. Exp Neurol. 2010;221(2):320–28.
   PubMed Web of Science ®Google Scholar
• Patassini S, Giampà C, Martorana A, Bernardi G, Fusco FR. Effects of simvastatin on neuroprotection and modulation of Bcl-2 and BAX in the rat quinolinic acid model of Huntington's disease. Neurosci Lett. 2008;448(1):166–69.
   PubMed Web of Science ®Google Scholar
• Goldstein LB, Bushnell CD, Adams RJ, Appel LJ, Braun LT, Chaturvedi S, Creager MA, Culebras A, Eckel RH, Hart RG, Hinchey JA, Howard VJ, Jauch EC, Levine SR, Meschia JF, Moore WS, Nixon JV, Pearson TA. Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42(2):517–84.
   PubMed Web of Science ®Google Scholar
• Furie KL, Kasner SE, Adams RJ, Albers GW, Bush RL, Fagan SC, Halperin JL, Johnston SC, Katzan I, Kernan WN, Mitchell PH, Ovbiagele B, Palesch YY, Sacco RL, Schwamm LH, Wassertheil-Smoller S, Turan TN, Wentworth D. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42(1):227–76.
   PubMed Web of Science ®Google Scholar
• Rajabally YA, Varakantam V, Abbott RJ. Disorder resembling Guillain-Barré syndrome on initiation of statin therapy. Muscle Nerve. 2004;30(5):663–66.
   PubMed Web of Science ®Google Scholar
• Scola RH, Trentin AP, Germiniani FM, Piovesan EJ, Werneck LC. Simvastatin-induced mononeuropathy multiplex: case report. Arq Neuropsiquiatr. 2004;62(2B):540–42.
   PubMed Web of Science ®Google Scholar
• Abellán-Miralles I, Sánchez-Pérez RM, Pérez-Carmona N, Díaz-Marín C, Mallada-Frechín J. Multiple mononeuropathy associated to treatment with pravastatin. Rev Neurol. 2006;43(11):659–61.
   PubMed Web of Science ®Google Scholar
• Miesbach W, Chapman J, Scharrer I. Focal seizures after treatment with fluvastatin in a patient with a history of catastrophic antiphospholipid syndrome. J Neurol Sci. 2005;238(1–2):93–95.
   PubMed Web of Science ®Google Scholar
• Serbanescu I, Ryan MA, Shukla R, Cortez MA, Snead OC 3rd, Cunnane SC. Lovastatin exacerbates atypical absence seizures with only minimal effects on brain sterols. J Lipid Res. 2004;45(11):2038–43.
   PubMed Web of Science ®Google Scholar
• Frederiksen JL. Simvastatin as an add-on treatment to copaxone for the treatment of relapsing multiple sclerosis. Glostrup University Hospital. Clinicaltrial gov NCT00429442.
   Google Scholar
• Frederiksen JL. Simvastatin treatment of patients with acute optic neuritis. Glostrup University Hospital. Clinicaltrial gov NCT00261326.
   Google Scholar
• Valone F. Immunotherapy with BHT-3009 alone or combined with atorvastatin in patients with multiple sclerosis. Clinicaltrial gov NCT00103974.
   Google Scholar
• Damier P. Safety and efficacy of pravastatin in relapsing-remitting multiple sclerosis. Nantes University Hospital. Clinicaltrial gov NCT00200655.
   Google Scholar
• Matsumoto M. Japan statin treatment against recurrent stroke (J-STARS). Hiroshima University. Clinicaltrial gov NCT00221104.
   Google Scholar
• Heo JH. The effects of very early use of rosuvastatin in preventing recurrence of ischemic stroke. Severance Hospital. Clinicaltrial gov NCT01364220.
   Google Scholar
• Migrino R. Carotid plaque regression with statin treatment assessed by high field magnetic resonance imaging. Medical College of Wisconsin. Clinicaltrial gov NCT00388843.
   Google Scholar
• Kazui H. The clinical study of pitavastatin treatment for group of mild to moderate Alzheimer's disease. Osaka University. Clinicaltrial gov NCT00548145.
   Google Scholar
• Carlsson CM. To evaluate the safety and effectiveness of atorvastatin plus a cholinesterase inhibitor in AD patients. Pfizer. Clinicaltrial gov NCT00151502.
   Google Scholar
• Figueiredo E. The role of statins in preventing cerebral vasospasm secondary to subarachnoid hemorrhage. University of Sao Paulo General Hospital. Clinicaltrial gov NCT01346748.
   Google Scholar
• Diringer M. Statins and cerebral blood flow in subarachnoid hemorrhage. Washington University School of Medicine. Clinicaltrial gov NCT00795288.
   Google Scholar